Izrael - hebrajski - Ministry of Health

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (lhrh) analog therapy or surgical castration.

Izrael - hebrajski - Ministry of Health

novartis israel ltd - letrozole - טבליות מצופות פילם - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Izrael - hebrajski - Ministry of Health

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Izrael - hebrajski - Ministry of Health

bioavenir ltd, israel - letrozole - טבליות מצופות פילם - letrozole 2.5 mg - letrozole - letrozole - letrozole farmoz tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole farmoz is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Izrael - hebrajski - Ministry of Health

perrigo israel agencies ltd - letrozole 2.5 mg - film coated tablets - letrozole - • femozol (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer . • femozol is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy .• extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy .• adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer .

Izrael - hebrajski - Ministry of Health

inovamed ltd - letrozole 2.5 mg - film coated tablets - letrozole - for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy.adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Izrael - hebrajski - Ministry of Health

dexcel ltd, israel - letrozole - טבליות מצופות פילם - letrozole 2.5 mg - letrozole - letrozole - letrozole - dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. letrozole - dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Izrael - hebrajski - Ministry of Health

rafa laboratories ltd - letrozole 2.5 mg - film coated tablets - letrozole - letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Izrael - hebrajski - Ministry of Health

novartis israel ltd - budesonide - קפסולות - budesonide 200 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

Izrael - hebrajski - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.